Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) EV/FCF
As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a EV/FCF of 46.2×. Over the past ten years it has ranged from 8.2× (April 2018) to 344× (April 2021); the current reading is higher than 72% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 41.4× | (16.72%) |
| FY2024 | 49.8× | 58.62% |
| FY2023 | 31.4× | 20.12% |
| FY2022 | 26.1× | (53.02%) |
| FY2021 | 55.6× | 14.24% |
| FY2020 | 48.7× | (22.68%) |
| FY2019 | 62.9× | 294.13% |
| FY2018 | 16.0× | 64.91% |
| FY2017 | 9.7× | (13.24%) |
| FY2016 | 11.2× | (0.05%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 44.3× | 18.38% |
| Jun 2026 | 37.4× | (3.47%) |
| Mar 2026 | 38.8× | (6.49%) |
| Dec 2025 | 41.4× | (32.39%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | 11.4× |
| TAK Takeda Pharmaceutical Co. compare | 11.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.5× |
| VTRS Viatris Inc. compare | 16.3× |
| ZTS Zoetis Inc. compare | 18.4× |
| UTHR United Therapeutics Corporation compare | 24.2× |
| ELAN Elanco Animal Health Incorporated compare | 42.7× |
| TEVA Teva Pharmaceutical Industries Ltd. | 46.2× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement